Literature DB >> 20498631

Human FOXP3 and cancer.

F Martin1, S Ladoire, G Mignot, L Apetoh, F Ghiringhelli.   

Abstract

FOXP3 is a transcription factor necessary and sufficient for induction of the immunosuppressive functions in regulatory T lymphocytes. Its expression was first considered as specific of this cell type, but FOXP3 can also be transiently expressed in T-cell antigen receptor-activated human nonregulatory T cells. Recent data indicate that FOXP3 is also expressed by some nonlymphoid cells, in which it can repress various oncogenes that are restored following FOXP3 deletion or mutation. This review summarizes major advances in (1) the understanding of Foxp3 functions in human regulatory T cells, (2) the prognostic significance of Foxp3-expressing T cells in human malignancies and (3) the significance of Foxp3 expression in human tumor cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20498631     DOI: 10.1038/onc.2010.174

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

Review 1.  FOXP3 as an X-linked tumor suppressor.

Authors:  Lizhong Wang; Runhua Liu; Mark Ribick; Pan Zheng; Yang Liu
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

2.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

3.  17 β-estradiol suppresses Helicobacter pylori-induced gastric pathology in male hypergastrinemic INS-GAS mice.

Authors:  Masahiro Ohtani; Zhongming Ge; Alexis García; Arlin B Rogers; Sureshkumar Muthupalani; Nancy S Taylor; Shilu Xu; Koichiro Watanabe; Yan Feng; Robert P Marini; Mark T Whary; Timothy C Wang; James G Fox
Journal:  Carcinogenesis       Date:  2011-05-11       Impact factor: 4.944

Review 4.  Towards tumor immunodiagnostics.

Authors:  Helen Kourea; Vassiliki Kotoula
Journal:  Ann Transl Med       Date:  2016-07

5.  CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma.

Authors:  Elena Sanmartín; Fernando Ortiz-Martínez; Eloy Pomares-Navarro; Araceli García-Martínez; Montserrat Rodrigo-Baños; Marta García-Escolano; Leire Andrés; Enrique Lerma; Francisco I Aranda; Pascual Martínez-Peinado; José M Sempere-Ortells; Gloria Peiró
Journal:  Virchows Arch       Date:  2016-11-24       Impact factor: 4.064

6.  miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

Authors:  Avital Gaziel-Sovran; Miguel F Segura; Raffaella Di Micco; Mary K Collins; Douglas Hanniford; Eleazar Vega-Saenz de Miera; John F Rakus; John F Dankert; Shulian Shang; Robert S Kerbel; Nina Bhardwaj; Yongzhao Shao; Farbod Darvishian; Jiri Zavadil; Adrian Erlebacher; Lara K Mahal; Iman Osman; Eva Hernando
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

Review 7.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

8.  Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma.

Authors:  Sita S Withers; Katherine A Skorupski; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Carlos O Rodriguez; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2018-09-19       Impact factor: 2.613

9.  Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Authors:  C Mirjolet; C Charon-Barra; S Ladoire; F Arbez-Gindre; A Bertaut; F Ghiringhelli; A Leroux; D Peiffert; C Borg; J F Bosset; G Créhange
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 10.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.